Previous 10 | Next 10 |
home / stock / nvo / nvo articles
Viking Therapeutics Inc (NASDAQ:VKTX) recently released top-line results from a successful Phase 2 weight loss trial. Patients receiving VK2735 d...
Eli Lilly And Co’s (NYSE:LLY) CEO, David Ricks, shared the pharmaceutical giant’s plans to introduce its obesity drug, tirzepatide...
A recent study by the Pew Research Center has shown that a majority of Americans are doubtful about the potential of new weight loss drugs, such as...
Amgen Inc (NASDAQ:AMGN) is expected to unveil updates on various programs this year, targeting significant markets. Despite concern...
The race for new drugs to fight obesity and associated diabetes and cardiovascular diseases heated up on Monday after positive results from trials ...
Goldman Sachs economists foresee a potential 1% boost to the United States’ Gross Domestic Product (GDP) in the coming years, attributin...
While Novo Nordisk A/S (NYSE:NVO) faces challenges in meeting the global demand for its highly sought-after weight-loss treatment, Wegovy...
At the Consumer Analyst Group of New York Conference in Boca Raton, Florida, Conagra Brands Inc (NYSE:CAG) Executive Tom McGough&nbs...
The rising popularity of weight-loss drugs like Ozempic is now pressuring food companies to reevaluate their business strategies. According to a re...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...